EFFECTS OF EXTRACORPOREAL CYTOKINE ELIMINATION ON HEMODYNAMIA AND MORTALITY IN CRITICAL PATIENTS
- Conditions
- Cytokine Hemadsorption Therapy in Critically Ill Patients Who Have no Microbiological Findings and Develop Vasoplegic Shock
- Registration Number
- NCT05984407
- Lead Sponsor
- Hakan Küçükkepeci
- Brief Summary
Observation of the effects of cytokine adsorbent hemadsorption therapy on hemodynamics and mortality in critically ill patients who developed vasoplegic shock due to hyperinflammation without microbiological findings in the intensive care unit.
- Detailed Description
Observation of the effects of cytokine adsorbent hemadsorption therapy on hemodynamics and mortality in critically ill patients who developed vasoplegic shock due to hyperinflammation without microbiological findings and met the inclusion criteria in the Intensive Care Unit between 01.08.2023 and 01.02.2024
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- C-reactive protein (CRP) ≥ 100 mg/l
- Procalcitonin (PCT) < 2 ng/l
- Patients aged 18-80 years who were treated with cytokine adsorption due to vasoplegic shock
Exclusion Criteria
- Patients under 18 years of age
- Patients with suspected or proven bacterial cause of vasoplegic shock.
- Those who did not approve to participate in the study
- Patients without vasoplegic shock
- Patients with CRP < 100 mg/l, PCT ≥ 2 μg/L
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The time to resolution of vasoplegic shock within days. From enrollment to the end of treatment at 12 weeks
- Secondary Outcome Measures
Name Time Method 7-day mortality 7 days mortality until discharge from hospital From enrollment to the end of treatment at 12 weeks mechanical ventilation need and duration From enrollment to the end of treatment at 12 weeks duration of treatment in the intensive care unit From enrollment to the end of treatment at 12 weeks Interleukin 10 level on day 1 one day Interleukin 6 level on day 1 one day TNF - α level on day 1 one day Interleukin 1 beta level on day 3 3 days Interleukin 10 level on day 3 3 days Interleukin 6 level on day 3 3 days TNF - α level on day 3 3 days dose of catecholamine From enrollment to the end of treatment at 12 weeks Interleukin 1 beta level on day 1 one day
Trial Locations
- Locations (1)
Prof. Dr. Cemil Taşcıoğlu City Hospital
🇹🇷İstanbul, Şişli, Turkey
Prof. Dr. Cemil Taşcıoğlu City Hospital🇹🇷İstanbul, Şişli, Turkey